JDRF’s Role in Advancing Insulin Pump Technology and User Experience

The Juvenile Diabetes Research Foundation (JDRF) has long been a driving force in the fight against type 1 diabetes (T1D), funding groundbreaking research and advocating for better treatments. Among its most impactful areas of focus is the continuous improvement of insulin pump technology. For millions of people living with T1D, insulin pumps are not merely devices—they are essential tools that manage a chronic, demanding condition 24/7. JDRF’s efforts aim to transform these devices from basic delivery systems into intelligent, integrated companions that enhance clinical outcomes and everyday quality of life. By pushing for greater precision, usability, and connectivity, JDRF is shaping a future where diabetes management is less intrusive and more effective.

Insulin pumps offer significant advantages over multiple daily injections, including steadier insulin levels and greater flexibility. However, traditional pumps still require constant user vigilance. JDRF recognizes that the next leap forward depends on making pumps smarter, more automated, and truly user-centered. This involves everything from refining hardware design to developing sophisticated software algorithms. The foundation’s work spans early-stage research, clinical trials, policy advocacy, and direct collaboration with industry leaders. As a result, JDRF has become a central catalyst in the evolution of insulin pump technology, directly influencing how devices are built, regulated, and adopted by the diabetes community.

The Evolution of Insulin Pump Technology: A JDRF Perspective

Insulin pumps have come a long way since their introduction decades ago. Early models were bulky, limited in functionality, and required extensive user training. Over time, pumps became smaller, more reliable, and capable of delivering basal and bolus insulin with greater accuracy. JDRF recognized early that the true potential of pump therapy lay in integration—connecting pumps with continuous glucose monitors (CGMs) to create a feedback loop that could mimic a healthy pancreas. This vision led to significant investment in closed-loop, or hybrid closed-loop, systems often referred to as artificial pancreas technology.

JDRF has played a pivotal role in funding key clinical trials and fostering partnerships between academic researchers and device manufacturers. For example, the foundation supported pivotal studies that demonstrated the safety and efficacy of automated insulin delivery in children and adults. These studies provided the evidence needed for regulatory approvals and accelerated the commercial rollout of systems like Medtronic’s MiniMed 670G and 780G, Tandem’s Control-IQ, and Insulet’s Omnipod 5. Today, hybrid closed-loop pumps automatically adjust basal insulin delivery in response to CGM readings, significantly reducing time spent in hyperglycemia and hypoglycemia.

The evolution continues, with JDRF now focusing on fully automated, multi-hormone systems. These next-generation platforms aim not only to manage glucose levels but to anticipate and prevent dangerous fluctuations before they occur. The foundation’s research portfolio includes projects on faster-acting insulins, dual-hormone pumps (insulin and glucagon), and machine learning algorithms that personalize therapy in real time.

JDRF’s Key Initiatives in Pump Technology and User Experience

JDRF’s approach to improving insulin pump technology is multifaceted, encompassing direct research funding, advocacy for regulatory modernization, and the creation of open standards for device interoperability. These initiatives address both the technical performance of pumps and the practical realities of living with T1D.

Automated Insulin Delivery Systems

The development of automated insulin delivery (AID) systems is arguably JDRF’s most visible accomplishment. Through the JDRF Artificial Pancreas Project, the foundation invested over $100 million in research and development, catalyzing a field that was once considered speculative. Today, AID systems are the standard of care for many people with T1D. JDRF continues to fund refinements, including improved glucose prediction algorithms, adaptive learning features, and systems that require minimal user input. These systems reduce the mental load of diabetes management, allowing users to focus on daily life rather than constant decision-making.

Enhanced Mobile App Connectivity

Modern insulin pumps are increasingly paired with smartphone apps that display real-time data, deliver remote boluses, and provide alerts. JDRF has championed the integration of pumps with platforms like Tidepool and Dexcom’s Clarity, ensuring that users and their care teams have access to actionable insights. The foundation also supports the development of open-protocol pumps—devices that allow third-party developers to create custom apps and algorithms. This interoperability empowers users to choose the best combination of devices and software for their needs, accelerating innovation and personalization.

Designing Discreet, Comfortable Wearable Devices

Device size and form factor remain significant barriers to adoption, particularly among children, adolescents, and adults who lead active lifestyles. JDRF funds engineering projects focused on miniaturization, patch-pump designs (which eliminate tubing), and durable waterproofing. The goal is to create pumps that are as unobtrusive as possible, reducing the social burden associated with wearing a medical device. Discreet wear improves adherence and encourages consistent use, which directly correlates with better glycemic outcomes.

Educational Resources and Usability Research

Technology is only effective if people can use it correctly and confidently. JDRF invests in educational resources that help users master their devices, including video tutorials, quick-reference guides, and peer-support networks. The foundation also conducts usability research to identify common pain points—such as complex menu structures, difficult insertion processes, or confusing alarms—and works with manufacturers to address them. By prioritizing human-centered design, JDRF ensures that pumps are not only technologically advanced but also intuitive and forgiving in real-world use.

The Artificial Pancreas: From Vision to Reality

The term “artificial pancreas” refers to a system that automatically manages blood glucose levels by delivering insulin (and potentially other hormones) based on sensor data. JDRF’s commitment to this concept dates back to the mid-2000s, when the foundation launched a dedicated research initiative. This effort brought together endocrinologists, engineers, data scientists, and patient advocates to solve the technical and regulatory challenges associated with closed-loop control.

Early closed-loop systems required supervised, in-hospital studies. Through iterative research, JDRF-funded investigators developed algorithms that could operate safely in outpatient settings, handling the unpredictability of meals, exercise, and stress. The culmination of this work was the approval of the first hybrid closed-loop pump in 2016. Today’s systems, such as Tandem Diabetes Care’s t:slim X2 with Control-IQ technology, automatically adjust basal rates every five minutes and deliver correction boluses as needed. Clinical trials have shown these systems increase time-in-range (blood glucose 70–180 mg/dL) by 10–15 percentage points compared to sensor-augmented pump therapy, with corresponding reductions in HbA1c and hypoglycemia.

JDRF’s current focus is on advancing toward a fully closed-loop system—one that does not require meal announcements or carbohydrate counting. Researchers are exploring the use of computer vision (phone cameras) to estimate meal composition, smart insulin patches that release insulin in response to glucose levels, and dual-hormone systems that deliver glucagon to prevent low blood sugar. JDRF is also funding studies on how artificial intelligence can learn individual insulin sensitivity patterns over time, making adjustments proactively rather than reactively.

Improving User Experience: Beyond Clinical Efficacy

While clinical outcomes are paramount, JDRF recognizes that user experience is equally critical to the success of insulin pump technology. A device that feels burdensome, confusing, or stigmatizing will not be used consistently, undermining its medical benefits. JDRF’s user experience efforts focus on three main areas: human factors engineering, psychological support, and community engagement.

Human Factors and Interface Design

Complex menu navigation, small screens, and unintuitive alarm messages are common complaints among pump users. JDRF collaborates with designers and behavioral scientists to create interfaces that reduce cognitive load. Features such as simplified setup wizards, customizable alerts, and gesture-based controls are being developed to accommodate users of all ages and technical backgrounds. The foundation also advocates for larger font sizes, high-contrast displays, and voice control to improve accessibility for those with visual or motor impairments.

Reducing Alarm Fatigue

One of the most cited frustrations with pump therapy is the frequency and intrusiveness of alarms. JDRF is funding research into smarter alarm systems that prioritize clinically significant events while minimizing alerts for out-of-range readings that are transient or easily corrected. Machine learning can help distinguish between patterns that require immediate attention and those that can be addressed later. Some new systems use adaptive thresholds that learn a user’s typical glucose variability, reducing false alarms and improving trust in the device.

Building Confidence Through Training and Support

Transitioning to a new pump or upgrading to an automated system can be daunting. JDRF supports peer-to-peer mentoring programs, online forums, and certified diabetes educator training to help users build competence and confidence. The foundation also works with healthcare providers to develop standardized training curricula that cover not only device operation but also troubleshooting, sick-day management, and travel planning. Comprehensive training reduces errors and anxiety, leading to better long-term satisfaction.

Interoperability and Open Standards: JDRF’s Advocacy Role

A critical barrier to optimal pump therapy has been the lack of interoperability between devices from different manufacturers. In the past, patients were often locked into a single brand’s ecosystem, unable to mix and match components. JDRF was a strong proponent of the #WeAreNotWaiting movement and the development of open-source artificial pancreas systems, such as OpenAPS and Loop. The foundation has advocated for regulatory frameworks that encourage device manufacturers to adopt common data standards and communication protocols. This pressure has led to industry initiatives like the Tidepool Loop platform, which aims to create a universal, compatible controller for AID systems. Interoperability empowers users to choose best-in-class components and fosters competition, driving down costs and accelerating innovation.

JDRF also works with the FDA and international regulators to streamline approval processes for interoperable components. Clear guidance on safety and efficacy requirements for modular systems allows manufacturers to bring new products to market faster. This regulatory clarity is essential for realizing the vision of a fully personalized, modular pump system where users can mix sensors, pumps, and controllers from different sources.

Collaborations and Partnerships That Drive Innovation

JDRF’s impact is amplified by its ability to convene diverse stakeholders. The foundation partners with academic institutions such as the University of Virginia, Stanford, and the Mayo Clinic to conduct foundational research. It collaborates with industry leaders—including Medtronic, Tandem, Insulet, Dexcom, Abbott, and Lilly—on product development and clinical trials. JDRF also engages with technology companies like Google and Apple to explore how their platforms can integrate with diabetes devices. These partnerships ensure that research findings are translated into practical products that reach patients in a timely manner.

In addition to corporate and academic alliances, JDRF works closely with patient advocacy groups, diabetes organizations, and government agencies. The foundation participates in the Diabetes Technology Society and the European Association for the Study of Diabetes to disseminate best practices and harmonize guidelines. Through these networks, JDRF amplifies the voice of the T1D community, ensuring that user needs remain central to the innovation agenda.

The Future of Insulin Pump Technology: JDRF’s Vision

Looking forward, JDRF envisions a world where insulin pump technology is nearly invisible, fully autonomous, and deeply integrated with other health management systems. The next generation of pumps will leverage artificial intelligence to learn each user’s unique physiology, predict glucose excursions hours in advance, and adjust delivery proactively. These systems will communicate with smartwatches, digital assistants, and electronic health records, creating a seamless flow of information that empowers both patients and clinicians.

JDRF is also exploring the potential of bi-hormonal systems that deliver both insulin and glucagon, effectively mimicking the natural pancreatic response to both high and low blood glucose. Early prototypes have shown promising results in clinical trials, reducing hypoglycemia risk while maintaining excellent time-in-range. The foundation is supporting research into stable glucagon formulations and miniaturized dual-chamber pump designs that could make these systems practical for daily use.

Another frontier is the use of adaptive algorithms that incorporate contextual data—such as physical activity, sleep patterns, stress levels, and menstrual cycle phases—to refine insulin delivery. Machine learning models trained on large datasets can detect subtle correlations that human clinicians might miss, enabling truly personalized therapy. JDRF is funding longitudinal studies to generate the evidence base needed for regulatory approval of AI-driven dose adjustment.

Beyond the technology itself, JDRF is committed to ensuring equitable access to these innovations. The foundation advocates for insurance coverage, reimbursement policies, and prescription practices that do not create barriers based on income, geography, or age. JDRF works with policymakers to address disparities in diabetes technology adoption, particularly among minority populations and those in underserved communities. The ultimate goal is that every person with T1D who could benefit from advanced pump therapy can access it.

JDRF’s Ongoing Commitment to the Diabetes Community

JDRF’s efforts to improve insulin pump technology are part of a broader mission to accelerate life-changing breakthroughs for people with T1D. The foundation’s research portfolio encompasses not only devices but also beta cell replacement therapies, immunotherapies, and prevention strategies. By creating a comprehensive ecosystem of innovation, JDRF aims to move beyond management toward a cure. However, until that cure is found, improving the tools available for daily management remains a top priority.

The foundation’s impact is measured not just in publications and patents but in the lived experiences of millions of users. Young children who can attend sleepovers without fear of severe hypoglycemia. Teenagers who can wear their pumps discreetly under their clothes. Adults who wake up with blood glucose already in range because their pump adjusted overnight. These everyday victories are the true testament to JDRF’s work.

For those interested in learning more about JDRF’s current initiatives and how to get involved, visit the JDRF official website. Detailed information about approved artificial pancreas systems can be found through the FDA Artificial Pancreas Device System page. To explore user-centered design in diabetes technology, the Diabetes Technology Society offers guidelines and research summaries.

The journey from bulky, manual pumps to intelligent, adaptive systems has been remarkable, and JDRF has been a constant force for progress. By funding bold ideas, advocating for user-friendly design, and forging collaborations across sectors, the foundation ensures that the future of insulin pump technology is brighter than ever. For the millions living with T1D, that future cannot arrive soon enough.